期刊
SCIENCE
卷 359, 期 6372, 页码 175-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aan4672
关键词
-
资金
- Takara Bio
- Beam Therapeutics
- Editas Medicine
- Pairwise Plants
- BioMarin Pharmaceutical
- Juno Therapeutics
- Fate Therapeutics
After almost 30 years of promise tempered by setbacks, gene therapies are rapidly becoming a critical component of the therapeutic armamentarium for a variety of inherited and acquired human diseases. Gene therapies for inherited immune disorders, hemophilia, eye and neurodegenerative disorders, and lymphoid cancers recently progressed to approved drug status in the United States and Europe, or are anticipated to receive approval in the near future. In this Review, we discuss milestones in the development of gene therapies, focusing on direct in vivo administration of viral vectors and adoptive transfer of genetically engineered T cells or hematopoietic stem cells. We also discuss emerging genome editing technologies that should further advance the scope and efficacy of gene therapy approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据